Redeye comments on Surgical Science dropping an absolute bomb of a press release.
Redeye initiates coverage of Ferroamp, a greentech company offering a modular hardware and software ...
Insplorion has announced that the ATEX certification process will be delayed by another estimated th...
We have updated our investment view on Mendus following its expanded strategy for vididencel to chro...
Redeye comments on CMS’s finalised reimbursement rates, effective from January 2026.
Redeye provides a short comment on Catella's divestment of Valuation France to Newmark Group, announ...
Redeye endorses today’s news that Sprint Bioscience has sold its TREX1 program to Gilead Sciences, i...
* Q3: +24% sales growth, 1.3% adj. EBIT margin * '25e-'27e adj.
Solwers' Q3 sales were in line with our expectation, while EBITA was 8% ahead of our estimate, a cl...
Flexion’s latest quarterly update marks a period of transition, with financial performance slightly ...
Redeye comments on EG7’s letter from Eros Capital which provides further details on the new largest ...
Solwers reported its results for Q3 with sales of EUR 17.
* Room for M&A to drive earnings growth * Funding costs are coming down significantly * 2026e P/CEPS...
Studentbostäder i Norden hyresintäkter steg med 6% till 112,8 mkr och driftnettot ökade med 9% till ...
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
